Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases—From pathophysiology to clinical practice
- 4 May 2016
- journal article
- review article
- Published by Wiley in Movement Disorders
- Vol. 31 (6) , 836-847
Abstract
This review provides an update on the role, development, and validation of CSF biomarkers in the diagnosis and prognosis of Alzheimer's disease and PD. Some recent developments on novel biomarkers are also discussed. We also give an overview of methodological/technical factors still hampering the global validation and standardization of CSF Alzheimer's disease and PD biomarkers. CSF biomarkers have the potential to improve the diagnostic accuracy at the early stages not only for Alzheimer's disease but also for PD. This step is essential in view of the availability of disease‐modifying treatments. Our vision for the future is that analyzing biomarker panels on a minute amount of CSF could provide important information on the whole spectrum of the molecular pathogenic events characterizing these neurodegenerative disorders. CSF core biomarkers have already been included in the diagnostic criteria for Alzheimer's disease, and they are also under consideration as tools to monitor the effects of disease‐modifying drugs. With respect to PD, their potential for improving diagnostic accuracy in early diagnosis is under intense research, resembling the same path followed for Alzheimer's disease. © 2016 International Parkinson and Movement Disorder SocietyKeywords
This publication has 158 references indexed in Scilit:
- Glucocerebrosidase deficiency in substantia nigra of parkinson disease brainsAnnals of Neurology, 2012
- Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementiaNeurobiology of Aging, 2011
- Gaucher Disease Glucocerebrosidase and α-Synuclein Form a Bidirectional Pathogenic Loop in SynucleinopathiesCell, 2011
- Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progressionAnnals of Neurology, 2010
- Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disordersActa Neuropathologica, 2010
- The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementiaActa Neuropathologica, 2010
- Cerebrospinal Fluid Biomarkers and Rate of Cognitive Decline in Very Mild Dementia of the Alzheimer TypeArchives of Neurology, 2009
- Prediction and longitudinal study of CSF biomarkers in mild cognitive impairmentNeurobiology of Aging, 2009
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009
- Applicability of current staging/categorization of α-synuclein pathology and their clinical relevanceActa Neuropathologica, 2008